The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models (Q38480031)

3 September 2017

title

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models (English)

1 reference

3 September 2017

1 reference

1 reference

Young-Soon Na

1

1 reference

3 September 2017

Kyung-Ah Jung

2

1 reference

3 September 2017

Seung-Mi Kim

3

1 reference

3 September 2017

Yong Sang Hong

4

1 reference

3 September 2017

Min-Hee Ryu

5

1 reference

3 September 2017

Se Jin Jang

6

1 reference

3 September 2017

Dae Hyuk Moon

7

1 reference

3 September 2017

Dong-Hyung Cho

8

1 reference

3 September 2017

Jin Cheon Kim

9

1 reference

3 September 2017

Jung Shin Lee

10

1 reference

3 September 2017

Tae Won Kim

11

1 reference

3 September 2017

publication date

3 November 2010

1 reference

Cancer Chemotherapy and Pharmacology

3 September 2017

published in

1 reference

3 September 2017

volume

68

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

389-398

1 reference

3 September 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Irinotecan therapy and molecular targets in colorectal cancer: a systemic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Next generation topoisomerase I inhibitors: Rationale and biomarker strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Histone deacetylase inhibitors: Potential in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Induction of fetal hemoglobin synthesis by valproate: modulation of MAP kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

HDACs and HDAC inhibitors in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Biomarkers for predicting clinical responses to HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

A new precursor for the radiosynthesis of [18F]FLT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

HDAC inhibitors: clinical update and mechanism-based potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Drug resistance and the solid tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

Enhancement of chemotherapy by manipulation of tumour pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1495-6

10.1007/S00280-010-1495-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1026202228

0 references

1 reference